

The Annual General Pediatric Review & Self Assessment



STATISTICS & EBM

Rani S. Gereige, MD, MPH, FAAP

Executive Director of Medical Education &

Designated Institutional Official (DIO)

Nicklaus Children's Hospital

Clinical Professor of Pediatrics

Florida International University College of Medicine

Miami, Florida

Rani.Gereige@Nicklaushealth.org



Disclosure of Relevant Relationship

Dr. Gereige has not had (in the past 24 months) any relevant conflicts of interest or relevant financial relationship with the manufacturers of products or services that will be discussed in this CME activity or in his presentation.

Dr. Gereige will support this presentation and clinical recommendations with the “best available evidence” from medical literature.

Dr. Gereige does not intend to discuss an unapproved/investigative use of a commercial product/device in this presentation.

PREP Self-Assessment Content Specifications

What You Need to Know?



Research & Statistics

A. Study design: Understand the following:

1. **Validity hierarchy** for study design and study type
2. The uses and limitations of:
 - ✓ **Randomized clinical trials**
 - ✓ **Controlled clinical trials**
 - ✓ **Cohort studies**
 - ✓ **Case-control studies**
 - ✓ **Cross-sectional and longitudinal studies**
 - ✓ **Systematic review and meta-analysis**
 - ✓ **Descriptive epidemiologic studies**
 - ✓ **Case reports/series** and anecdotal evidence
3. How **sample size** affects the **power** of a study
4. How sample size may limit the ability to detect adverse events
5. Identify the **study design** most likely to yield valid information about:
 - ✓ The accuracy of a **diagnostic test**
 - ✓ The **benefits and/or harms** of an intervention
 - ✓ The **prognosis** of a condition

B. Data analysis

1. Understand:
 - ✓ **Validity** and how it might be compromised
 - ✓ **Reliability** and how it might be compromised
 - ✓ **Bias** and how it might distort the estimate of the association between exposure and outcome
 - ✓ **Confounding** and how to control for it in a study
 - ✓ **Generalizability** and how it relates to validity
 - ✓ The concept of **intention-to-treat analysis** to maintain the power of a study
 - ✓ The concept of **number-needed-to-treat** when utilized to describe therapeutic interventions
2. Distinguish between **type I and type II statistical errors**
3. Assess how the **data source** (eg, diaries, billing data, discharge diagnostic code) may affect study results

Ref: AAP - 2013-2017 PREP SA



Research & Statistics (Cont'ed)

C. Reading and interpreting results

1. Understand the following:
 - ✓ Prevalence and incidence
 - ✓ Pre-test and post-test probability
 - ✓ Positive and negative predictive values
 - ✓ Sensitivity and specificity and how to apply them to test results
 - ✓ Standard deviation in the interpretation of results
 - ✓ Standard error in the interpretation of results
 - ✓ Confidence interval in the interpretation of results
 - ✓ Likelihood ratio and when it might be useful to reach a diagnosis
 - ✓ Relative risk analysis and odds ratio
2. Distinguish **statistical significance** from clinical importance
3. Given the need for specific clinical information, identify a clear, structured, searchable **clinical question**



Ref: AAP - 2013-2017 PREP SA





bar inference
 analysis **sample** inferences
 population precision research
 make dichotomous
 ordinal **biostatistical** variables estimate
 outcomes continuous
 classified generalizable endpoints
 subset histogram prevalence question
 range categorical random
 chart analyses

BASIC BIOSTATISTICS



Not all variables expressed in numbers are quantitative type of data

Data

Quantitative (Numerical)

Continuous variables

Discrete variables

Qualitative (Categorical)

Nominal variables

Ordinal Variables

* Expressed in numbers

Quantitative (Numerical)

Continuous Variables

- NUMERICAL data
- Can take any value in the range or scale of measure
- e.g. Age (2, 2.5, 3.5 years); Weight, Height, BP

- Data consists of COUNTS
- Usually integer (no decimals)
- e.g. No. of children; No. of admissions; No. of cigarettes smoked

Discrete Variables

* Expressed in terms of natural language description

* Can be named

* Represent Categories/groups

* Cannot be measured but counted

* e.g. Gender (M, F); Bld Group; Pain Severity (Mild, Mod, Severe); or Likert Scale

Qualitative (Categorical)

Nominal Variables

- NO order/ No Ranking
- Dichotomous (M; F or dead/alive) or Non-dichotomous (Bld Grp, Ethnicity)

- Ordered/ Ranked categories (e.g. Cancer Stage, Pain Severity, Likert Scale) Versus discrete data

- Difference between ranks is not a numeric value

Ordinal Variables (Ranked)

Nominal Variable
No one category has higher value than the others



Descriptive Statistics – Characteristics include:

Central Tendency


- Estimate of “center” of a distribution of values

Distribution of Data

- Normal (parametric distribution)
- Non-normal (non-parametric)
- Presented as frequency distribution

Dispersion/ Variation

- Spread of values around the central tendency



Measures of Central Tendency

Estimate of center of distribution of values. Three types of estimates

Mean

- **Average** of all values (uses ALL values in a sample)
- **Most commonly used** measure of central tendency
- Used in many statistical equations
- Influenced by extreme values (Skewed distribution)

Median

- **Exact middle of a set** of “ordered” values
- **Less sensitive to extreme values**
- **Better measure of a central tendency in highly skewed distributions** eg. Family income
- Should be accompanied by inter-quartile range (IQR)
 - eg. Family income: median\$ 25,000 (25-75 centile range 15,000-45,000)

Mode

- **most frequently occurring** value in a set
- It is only measure of central tendency for **nominal data**
- Has a high sample fluctuations
- A sample may have more than one mode (multimodal distribution)
- Eg: *O +ve is the most frequent blood group in US*


Distribution of Data



HINT:


- “Skeweness” side (R/L) follows the “tail” portion
- “Mean” is to the side of the tail to the median

- Normal distribution:
 - Mean=median=mode
- Skewed **to left** distribution:
 - Mean<median
 - Eg: *birth weight in an NICU*
- Skewed **to right** distribution
 - Mean>median
 - Eg: *income*



Measures of Variation/ Dispersion/ Spread

- Inter-quartile range
 - Around **Median**
- Variance
- Standard Deviation = the positive square root of the Variance
 - Around **Mean**
 - 95% sample data with 1.96 SD on each side of the mean
- **Range** = Largest value – Smallest value



Confidence Intervals

- An estimate of a population parameter
- Stated as a range between a lower and upper limit with a specific degree of certainty
- For a given sample size, if you want **more confidence** that your interval will be correct, you will have a wider interval and therefore, a **less precise** estimate
- The most commonly used level of certainty is **95%**

Example: *Imagine you're estimating the average weight gain in infants during their first year. By calculating a confidence interval around this estimate, you provide a range within which the true average weight gain likely falls, based on your sample*



Hypothesis Testing


- A hypothesis = A tentative explanation
 - We seek to prove or disprove the explanation
- Stated as a **pair of statements**
 - The Null Hypothesis (H_0)
 - A hypothesis which the researcher **tries to disprove, reject, or nullify**
 - True until evidence indicates otherwise
 - If you can conclude that H_0 is false (reject H_0), then the H_1 must be true
 - The Alternative Hypothesis (H_1)
 - Represents the conclusion reached by rejecting H_0
 - We reject H_0 if the evidence from the sample indicates that H_0 is unlikely to be true



Hypothesis Testing

Probabilities of Type I and Type II Error

STATISTICAL DECISION (Investigator's Conclusion)	ACTUAL SITUATION	
	H ₀ IS TRUE	H ₀ IS FALSE
REJECT THE H ₀	TYPE I ERROR = α (FALSE POSITIVE STUDY)	CORRECT DECISION = $1 - \beta$ (POWER) (TRUE POSITIVE STUDY)
DO NOT REJECT THE H ₀	CORRECT DECISION = $1 - \alpha$ (CONFIDENCE) (TRUE NEGATIVE STUDY)	TYPE II ERROR = β (FALSE NEGATIVE STUDY)



Type I Error

Erroneously concluding H₀ to be false

Rejecting H₀ when it is true

False positive study

Type II Error

Erroneously concluding H₀ to be true

Accepting H₀ when it is false

False negative study

α level

- The chance (probability) of rejecting H₀ when it is true is α level
- **The chance of Type I error is α level**
- The chance of false positive study is α level


β level

- The chance (probability) of accepting H₀ when it is false is β level
- **The chance of Type II error is β level**
- The chance of false negative study is β level

Sample Size

Effect size

The smaller the effect size, the larger the sample size required



The p-Value

- The actual risk of having a type I error
- AKA the “**observed**” level of significance
- Represents the chance of detecting a difference (inequality) in the parameters by chance when in fact there is no difference at all
- There is not a firm division between what scientists consider true and not true, but traditionally a **p-value of 0.05 or less** has been accepted as evidence of actual difference
- If p were 0.05 this means there is one chance in 20 that you could detect a difference (rejected H_0) by pure chance when in reality there was no real difference (H_0 is true)

**** α is set by investigators ****

**** p-value is calculated ****



Validity

EBM/
Statistics

Internal Validity

- Accuracy of study's conclusion
- Needed to determine the causal relations among variables

External validity

- How well the study represents the "real world"
- Generalizability
- Applicability

Clinical
Application

MedEd
Nicklaus
Children's
Hospital

Nicklaus
Children's
Hospital

Accuracy and Precision

Accuracy (Validity)

- The closeness of a measurement to the true value of the quantity that is measured.
- Affected by **systematic errors**

Precision (Repeatability; reliability)


- The closeness of agreement of two or more measurements of the same quantity.
- Affected by **random errors**

● True value;

● Measured value


A

Accurate
and
precise




B

Precise
but not
accurate




C

Accurate but not precise



D

Neither accurate nor precise



Study of Any Intervention

- Random Error = Deviation from the underlying truth **by chance**
- Bias = **Systematic** deviation from underlying truth
 - Definition of Bias:
 - “Any **systematic error** in the design, conduct or analysis of a study that results in a mistaken estimate of an exposure’s effect on the risk of disease.”
 - Major issue in epidemiologic research studies
 - Can lead to inferences that systematically deviate from truth



Common Types of Bias

- **Surveillance bias:** Population being monitored more closely or more frequently than the general population
- **Selection bias:** Two primary varieties:
 1. Systematic differences in the characteristics between individuals selected for a study compared with those not selected for the study
 2. Systematic differences in the selection of cases and controls or exposed and unexposed individuals
- **Misclassification bias:** Misclassifying individuals into diseased or non-diseased groups or into exposed and unexposed groups



Ways to Decrease Bias

(During Design, Before Completion, and After Completion)



(Before Study Completion) Ways to Decrease Bias

STRATEGY	BENEFITS	TRADE-OFF
Limitations for participation (Exclusion Criteria)	<ul style="list-style-type: none"> •By restricting the heterogeneity of the group, we reduce the opportunity for differences in outcome that aren't due to the treatment itself •Improves INTERNAL VALIDITY 	Makes generalization of the results more precise but limits EXTERNAL VALIDITY/ GENERALIZABILITY to a smaller portion of the population
Use of a Control/ Comparison Group	<p>Minimizes the ‘Hawthorne effect’</p> <p><i>By virtue of being in a study, the patient’s behavior changes and has a better prognosis</i></p>	<p>Still may have a “placebo effect” unless placebo given to control group</p> <p><i>Giving a pill with an expected/potential result can provide effect even if the pill is inert</i></p>
Randomization	<ul style="list-style-type: none"> • Equal & fair chance of getting intervention or control • Produce comparable groups in terms of general participant characteristics (known and unknown confounders) • The two groups will be similar at the baseline • Avoids selection bias 	Can limit generalizability (external validity)

Blinding & Allocation Concealment (Before & During)

Blinding/ Masking

- **Types of blinding**
 - Single-blind (subject or care giver)
 - Double-blind (subject and care giver)
 - Triple-blind (subject, care giver and data analyzer)
- **Open trial:** unblind or unmasked study
- **Benefit:** Removes the bias
 - Placebo effect
 - Observer bias (change in behavior due to the awareness of being observed; Hawthorne Effect)
 - Experimenter bias

Allocation Concealment

- Not same as “blinding”
- The subject and the investigator do not know the allocation of the group until randomization
 - After allocation it may or may not be blinded

(After Study Completion) Dealing With Confounding

Two ways

Stratification

- Subdividing subjects by levels of a potential KNOWN confounding variable
- Testing for the association of exposure with outcome within each stratum
- **Disadvantages:**
 - May not be feasible to handle multiple confounders
 - As the number of strata increase, sample size within each stratum decreases, reducing statistical power
 - May not adequately control for confounding

Multivariate Techniques

- Permit understanding of how much variability in an outcome is accounted for by a confounder
- Permit researchers to control for more factors than stratification
- **Disadvantages:**
 - Require readers to understand how to interpret the meaning of adjusted odds ratios and regression coefficients as well as how statistical significance was determined

Minimizing Bias & Decrease Confounding

STRATEGY	COMMENT
<i>Restriction or Specification (before)</i>	Limits the range of characteristics of the patients in the study, decreases sample size, heterogeneity and generalizability (External Validity)
<i>Matching (Before)</i>	For each patient in the study group, select one or more patients with the same characteristics for a comparison group
<i>Adjustment (After)</i>	Mathematical corrections to create an equal weight for dissimilar characteristics
<i>Stratification (After)</i>	Compare outcomes from subgroups of each group with similar characteristics (i.e. age by decades)
<i>Randomization (Before)</i>	Randomization of the study population and controls

Confounding

- One of several **threats to internal validity** of a research study
- Confounding is defined as:
 - A possible source of bias in studies in which an unmeasured third variable (the confounder) is related to the exposure of interest (although not causally) and causally related to the outcome of interest
- Best controlled by randomization



Randomization

What?

- Participation in a study arm by **chance**, not by choice
- Equal & fair chance of getting intervention or control

Goals

- **Produce comparable groups** in terms of general participant characteristics (known and unknown confounders)
- The two groups will be similar at the baseline
- **Avoids selection bias**

How?

- **Simple randomization:** repeated fair coin-tossing; good for large sample
- **Block randomization:** subjects randomized in a block (of 6 or 8) to prevent uneven allotment in a small sample
- **Stratified randomization:** randomize to groups according to covariates (like age groups under and over 12 years)



Potential Bias

Strategy Against



Sampling Bias

- Target population

Selection Bias

- Randomization

Placebo Effect

- Placebos
- Blinding participants

Cointerventions


- Blinding Providers
- Treatment protocols

Assessment Bias


- Blinding Providers

Follow-up

- Ensuring completeness




Research & Study Design



Studies in Medical Literature

- **Two** main categories:



Observational

- Studies in which subjects are observed (No Intervention)



Experimental

- Studies in which the effect of an intervention is observed



Observational Studies

Case Reports/ Case Series

Cross Sectional

Case-Control

Cohort



Observational Studies



CASE REPORTS/ CASE SERIES

- Observations, **small number** of patients
- **Simplest** design/ Descriptive
- Lead to hypothesis
- Over short period of time
- No controls
- **Easy** to write
- Subject to many biases
- **WEAKEST FORM OF EVIDENCE**

Observational Studies

Case Reports/ Case Series

Cross Sectional

Case-Control

Cohort



CROSS SECTIONAL

- AKA Surveys/ Epidemiologic/ Prevalence
- Short time (snapshot in time)
- What is happening now?
- Quick/ inexpensive

Observational Studies

Case Reports/ Case Series

Cross Sectional

Case-Control

Cohort



Observational Studies



CASE-CONTROL

- **Retrospective** (“what happened?”)
- Enrolls subjects **with disease/ outcome** (cases) and no disease (control) and ask about exposure
- Matching needed for controls
- Useful for **rare diseases** & **diseases that take long time** to develop
- Quickest/ cheap
- Large biases
- No estimate of disease incidence or prevalence
- Only allows to study **one outcome at a time**
- **You Calculate O.R.** (You do not have the whole population at Risk)




COHORT

- **Prospective** (“what will happen?”)
- Enrolls subjects **before the disease** and follow them forward looking for outcomes
- Estimates incidence or natural history of disease
- Useful to prove association between disease and exposure
- Cannot be used to prove causation
- Can be costly if long F/U (subject to patient attrition)
- May allow **multiple outcomes** assessment (clinical, economic, QOL, ..)

Cohort studies: marching towards outcomes (Prospective)

Looking forward in the past =
Retrospective Cohort




Lancet 2002; 359: 341-45

The defining characteristic of all cohort studies is that they track people forward in time **from exposure to outcome**. Data collection may be prospective or retrospective.
Ex. Contraceptives and DVT.

MedEd
Nicklaus
Children's
Hospital

Nicklaus
Children's
Hospital

Observational Studies



Longitudinal Studies

“Notion of Time”


Table. Summary of Designs

Study Design	Definition	Strengths	Weaknesses
Cross-Sectional	Single data collection point	<ul style="list-style-type: none"> • Quick • Inexpensive • Establishes prevalence • Suggests future research directions 	<ul style="list-style-type: none"> • Difficult to determine causality • Possible spurious associations
Longitudinal Prospective Retrospective	Multiple data collection points occur over time	<ul style="list-style-type: none"> • Can determine causality • Can monitor trends • Less concerned with spuriousness 	<ul style="list-style-type: none"> • Time-consuming • Expensive



Studies in Medical Literature

- **Two** main categories:



Observational

- Studies in which subjects are observed (No Intervention)



Experimental

- Studies in which the effect of an intervention is observed

Experimental Studies

AKA "Clinical Trials"

(easy to identify, explicitly stated in the abstract, Expensive)

Experimental Studies



Controlled Trials

Uncontrolled Trials

Self-Controls

- Subject to bias (Hawthorne effect)
- Can do crossover study (with washout period in between)

Independent Concurrent Controls

External Controls


- Uses the results of another investigator's research as a comparison
- Historical controls can also be used: for disease with no cures yet

RCT


- Considered the "gold standard"
- Double or single blind
- **The epitome of all research designs**
- Provides the strongest evidence of concluding causation
- Best insurance that results are due to the intervention

Non-Randomized

- Opened to biases




Classification of Types of Clinical Research



Hierarchy of Research Design

Best



Worst

Advantages and Limitations

- Pool results from **multiple** studies
- Findings offer a compilation of evidence (Greater power than an individual study)
- **Meta-analysis of multiple RCTs is the best**
- Meta-analysis = Systematic Review + analysis of results of multiple studies.
- The most significant limitation of both systematic reviews and meta-analyses is commonly described as “garbage in, garbage out.”




Reading & Interpreting Results (EBM)



The 5 Steps of Evidence-Based Medicine

It all starts with asking the right question



The five steps of evidence-based medicine include the 5 As: ask, acquire, appraise, apply, and assess.

MedEd

Nicklaus Children's Hospital



Nicklaus Children's Hospital

P.I.C.O. Question – 4 Components

- **P = Patient/Population and Problem:** Ask “how would I describe a group of patients similar to mine?” Balance precision with brevity, be specific
- **I = Intervention:** Ask “which main intervention am I considering?” (cause, prognostic factor, treatment, etc..)
- **C = Comparison/Control:** Ask “which is the main alternative to compare with the intervention?” again, be specific
- **O = Outcome of interest:** Ask “what can I hope to accomplish?” or “what could this exposure really affect?” again, be specific.




Incidence vs Prevalence

	Incidence	Prevalence
Calculation	$\frac{\text{\#New Events}}{\text{(Population at Risk)}}$	$\frac{\text{\#Total Existing Cases}}{\text{(Total Population)}}$
Time	During a specified time interval	At a given point in time
Interpretation	Provides an estimate of the probability (risk) that an individual will develop a disease during a specified period of time	Provides an estimate of the probability (risk) that an individual will be ill at a point in time <ul style="list-style-type: none">Quantifies the proportion of individuals in a population who have the disease at a specific instant



Studies and Clinical Questions

- Four possible Domains:



Therapy Studies

- Best is **RCT**, followed by Cohort (Same calculations)
 - Subjects randomized to: New Treatment (A) vs Old Treatment (B); or New Treatment vs Placebo
 - Outcome is measured (Improvement)

Are the results Clinically Significant?

	Outcome Present	Outcome Absent	Totals
Drug	A	B	A+B
Placebo	C	D	C+D
Totals	A + C	B + D	A+B+C+D

Control Event Rate

$$C_{ER} = C / C + D$$

Experimental Event Rate

$$E_{ER} = A / A + B$$

Absolute Risk Reduction

$$ARR = C_{ER} - E_{ER}$$

Relative Risk Reduction

$$RRR = (C_{ER} - E_{ER}) / C_{ER} = ARR / C_{ER}$$

Number Needed to Treat

$$NNT = 1 / ARR$$

- **Risk** is the probability of an event! = P(e)
- In statistics, **RISK** doesn't mean harmful events!

- Most of the times event rates are provided in the abstract as %
- Each event rate has a C.I.
- **NNT can only be calculated for statistically significant metrics (i.e. Look at the C.I.)**

Intention-to-Treat Principle

- **GOAL:** Preserves the randomization of unknown confounders
- Include all patients in the group they have randomized to, irrespective of the treatment received or not
- Include the subjects in the original group for analysis even if
 - They have stopped receiving the study intervention
 - They have crossed over to the counter intervention
 - They were lost to follow-up
 - Died
 - Left the study



Case-Control Studies

Odds Ratio (Relative Odds)

Adverse Outcome

	Present	Absent	Totals
Exposure Yes	a	b	a+b
Exposure No	c	d	c+d
Totals	a+c	b+d	a+b+c+d

$$OR = (a/c)/(b/d) = ad/bc$$

- Ratio of Odds
- The odds of a case patient being exposed divided by the odds of a control patient being exposed
- Calculated in Case-Control studies
- Proportion exposed in a diseased vs. non-diseased patient sample
- OR > 1 represents an increased risk or association
- Describes the relative harm of an exposure independent of disease prevalence
- When the prevalence of the outcome of interest is rare in the population from which the sample was drawn (often the reason for using a case-control study), the OR closely approximates the RR



Harm/ Association Studies

- RCT unethical
- Cohort is next best
- Outcome is measured (Harm)

You calculate a NNH

$$\text{NNH} = 1/\text{ARI}$$



Association is Different from Causation

- Five criteria must be fulfilled to prove causation:
 1. Is it clear that the **exposure preceded the onset of the outcome**? – Looks at exclusion criteria
 2. Is there a **dose-response** gradient?
 - e.g. Smoking and lung cancer
 3. Is there any positive evidence from a **de-challenge / re-challenge** study?
 4. Is the association **consistent** from study to study?
 5. Does the association make **biological sense**? - Pathophysiology



Diagnostic Test Studies

- All subjects receive the new test and the “gold standard”
e.g. Rapid Strep and throat culture

- 4 possibilities

By Gold Standard

	Patients with disease	Patients without disease
Test is positive	a true positive	b false positive
Test is negative	c false negative	d true negative

Evaluating the Evidence – Diagnostic Test

Construct the 2x2 table

	Patients with disease	Patients without disease
Test is positive	a true positive	b false positive
Test is negative	c false negative	d true negative

$\text{Sensitivity} = a / a+c = P(+/D) = P(\text{TP among diseased}) = \text{TP} / (\text{TP} + \text{FN})$
 $\text{Specificity} = d / b+d = P(-/\bar{D}) = P(\text{TN among non diseased}) = \text{TN} / (\text{FP} + \text{TN})$

$\text{PPV} = a / a+b = P(D/+) = P(\text{TP among all Positives}) = \text{TP} / (\text{TP} + \text{FP})$
 $\text{NPV} = d / c+d = P(\bar{D}/-) = P(\text{TN among all Negatives}) = \text{TN} / (\text{FN} + \text{TN})$

Sensitivity & Specificity of a Test

Sensitivity

- Ability of a test to recognize correctly persons who ***have a disease*** or condition
- Proportion of patients who have a disorder in whom the results of the test are *positive*

PID

(Positive in Disease)

Specificity

- Ability of a test to recognize correctly persons who ***do not have a disease*** or condition
- Proportion of patients who do not have a disorder in whom the test result is *negative*

NIH

(Negative in Health)

SpPin & SnNout



- **SpPin** = Result of a test with high **Sp**ecificity, when **P**ositive, rules **in** the diagnosis
- **SnNout** = Result of a test with high **S**ensitivity, when **N**egative, rules **out** the diagnosis

**Discriminant ability of a test =
(sensitivity+specificity)/2**



Predictive Values of a Test

PPV

- Proportion of patients **testing positive** who actually have the disease or condition in question

NPV

- Proportion of patients **testing negative** who actually *do not* have the condition in question

IMPORTANT



- Sensitivity and specificity are properties **intrinsic to a test** and are **not** affected by the prevalence of a particular disease or condition
- The predictive values of a diagnostic test are influenced greatly by prevalence. **The higher the disease prevalence, the higher the PPV.** e.g. The rapid flu test has a higher PPV during the flu season (time of high prevalence)



Likelihood Ratios

LR(+)

- Probability of person WITH disease having positive test/probability of person WITHOUT disease having a positive test
- $P(TP)/P(FP)$
- $LR(+) = \text{Sens}/(1-\text{spec})$
- Corresponds to clinically “ruling in disease”


LR(-)

- Probability of person WITH disease having negative test/probability of person WITHOUT disease having negative test
- $P(FN)/P(TN)$
- $LR(-) = (1-\text{sens})/\text{spec}$
- Corresponds to clinically “ruling out disease”

Indicate by how much a given diagnostic test result will raise or lower the pretest probability of the target disorder

- $LR = 1 \rightarrow$ Post-test probability = Pre-test probability
- $LR > 1 \rightarrow$ increases the probability that the target disorder is present
- $LR < 1 \rightarrow$ decreases the probability that the target disorder is present

Guide to the Significance of LRs



LR	Interpretation
> 10	Large and often conclusive increase in the likelihood of disease
5 - 10	Moderate increase in the likelihood of disease
2 - 5	Small increase in the likelihood of disease
1 - 2	Minimal increase in the likelihood of disease
1	No change in the likelihood of disease
0.5 - 1.0	Minimal decrease in the likelihood of disease
0.2 - 0.5	Small decrease in the likelihood of disease
0.1 - 0.2	Moderate decrease in the likelihood of disease
< 0.1	Large and often conclusive decrease in the likelihood of disease


- LR > 10 or < 0.1 generate large and often conclusive changes from pre-test to post-test probability
- LR = 5 - 10 or 0.1 - 0.2 generate moderate shifts pre-test to post-test
- LR = 2 - 5 or 0.5 - 0.2 generate small, but sometimes important changes in probability
- LR = 1 - 2 or 0.5 - 1 are rarely important shifts



Prognosis Studies

- RCTs are unethical and not feasible
- Cohort or Case-Control
- How likely are the outcomes over time?
 - Three ways of reporting it:
 - % Survival at a particular point in time (1 year or 5 year survival)
 - Median Survival (Length of F/U by which 50% of the study patients have died)
 - Survival Curves/ Kaplan-Meier Curve (% of study population at each point in time that is free of the specified outcome)





Median Survival:
 -Group 1: 23 years
 -Group 2: 8 Years

5-Year Survival:
 -Group 1: 100%
 -Group 2: 69%



Type of Question and Study Design




Type of Question	Suggested best type of Study
Therapy	RCT > cohort > case control > case series
Diagnosis	Prospective, blind comparison to a gold standard
Etiology/Harm	RCT > cohort > case control > case series
Prognosis	Cohort study > case control > case series
Prevention	RCT > cohort study > case control > case series
Clinical Exam	Prospective, blind comparison to gold standard
Cost	Economic analysis



Phases of Clinical Trials





SUMMARY SLIDES - Points to Remember



- α level is set by researcher (Usually at 0.05 or 5%), **p-value** is Calculated
- The smaller the set **p-value** (α level); the larger the sample size required
- A question about “**Precision**” of a measurement → refers to **C.I.**
- The sample size depends upon the power of the study: The higher the power ($1-\beta$), the larger the sample size required, and the lower the probability of Type II error
- Skewness side of a distribution follows the “Tail”, MEDIAN follows “tail” side
- Predictive value (NOT Sensitivity or Specificity) of a test, changes with prevalence of a disease in the community





Table. **Validity Hierarchy**

	Study Design	Strengths	Weaknesses
↑ Internal Validity	Randomized controlled trials	<ul style="list-style-type: none">● High internal validity● Reduced risk of confounding variables	<ul style="list-style-type: none">● Reduced external validity● Expensive, time-consuming
	Cohort studies	<ul style="list-style-type: none">● Useful for sequential events● Can study multiple outcomes● <i>Retrospective</i>: less expensive	<ul style="list-style-type: none">● Requires large sample size● Risk of confounding variables● Difficult to study rare outcomes● <i>Prospective</i>: Expensive
	Case-control studies	<ul style="list-style-type: none">● Useful for rare outcomes● Can study several exposures● Inexpensive	<ul style="list-style-type: none">● Risk of confounding variables
	Cross-sectional studies	<ul style="list-style-type: none">● Can study multiple outcomes and exposures	<ul style="list-style-type: none">● Cannot infer causality● Risk of confounding variables● Less useful for rare exposures or outcomes
	Case studies	<ul style="list-style-type: none">● Useful for rare outcomes● Convenient, inexpensive	<ul style="list-style-type: none">● Risk of confounding variables● Lack of a comparison group● Cannot infer causality




Adapted from Ho, et al. *Circulation*. 2008;118:1675–1684.

Common Statistical Tests



Data	Numerical (parametric)	Numerical (non-parametric) Ranks, Scores	Binomial (2 X 2)
Describe one group	Mean with Standard deviation	Median with Inter quartile range	Proportion or %
Compare two unpaired groups	Unpaired t-test	Mann-Whitney Test	Chi-square (Fisher's ≤ 5)
Compare two paired groups	Paired t-test	Wilcoxon test	McNemar's test
Compare ≥ 3 unmatched groups	One-way ANOVA	Kruskal-Wallis test	Chi-square
Compare ≥ 3 matched groups	Repeated-measures ANOVA	Friedman test	
Association between 2 variables	Pearson correlation	Spearman correlation	
Predict value from another variable	Simple linear (non-linear) regression	Non-parametric regression	Simple logistic regression
Predict value from several variable	Multiple linear (non-linear) regression		Multiple logistic regression



MedEd
Nicklaus
Children's
Hospital

The More I Think
The More Confused I Get





Spasibo Gracias | شكر
Grazie
Obrigado Spasibo Dank U
Eυχαριστώ Danke
Merci
Thank You
Ngiyabonga
Dank U
Diolch
Obrigado
Thank You
Tack
Dziękuję
Danke
Grazie
Merci
Dank U
תודה
Terima Kasih
Diolch
Grazie
Tack
Tack
Eυχαριστώ